<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03771040</url>
  </required_header>
  <id_info>
    <org_study_id>AB14001</org_study_id>
    <nct_id>NCT03771040</nct_id>
  </id_info>
  <brief_title>Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels</brief_title>
  <official_title>A Prospective, Multicenter, Randomised, Double-blind, Placebo-controlled, Phase 3 Study to Compare the Efficacy and the Safety of Masitinib Versus Placebo in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of masitinib (6 mg/kg/day) in&#xD;
      severe persistent asthma, uncontrolled with high dose of inhaled corticosteroid and with&#xD;
      elevated eosinophil levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Masitinib is a selective tyrosine kinase inhibitor. It is known that activation of&#xD;
      inflammatory cells, such as mast cells, and fibrous tissue remodeling are associated with&#xD;
      c-Kit, Lyn and PDGFR kinase signaling pathways; all key targets of masitinib. This is a&#xD;
      multicenter, double-blind, randomized, parallel-group (ascending dose titration of masitinib&#xD;
      to 6.0 mg/kg/day and matching placebo), comparative study of oral masitinib in the treatment&#xD;
      of patients with severe asthma, uncontrolled with high dose of inhaled corticosteroid and&#xD;
      with elevated eosinophil levels. Eligible patients will be treated during at least 48 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">September 2020</completion_date>
  <primary_completion_date type="Actual">September 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severe asthma exacerbation rate</measure>
    <time_frame>Duration of patient treatment exposure, assessed until withdrawal from study, study completion date, or for a maximum of 60 months</time_frame>
    <description>The number of severe asthma exacerbations over time frame of outcome measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asthma exacerbation rate</measure>
    <time_frame>Duration of patient treatment exposure, assessed until withdrawal from study, study completion date, or for a maximum of 60 months</time_frame>
    <description>The number of asthma exacerbations over time frame of outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Questionnaire (ACQ)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Asthma Control Questionnaire (ACQ)&#xD;
Type of questionnaire-description: A simple questionnaire to measure the adequacy of asthma control and change in asthma control which occurs either spontaneously or as a result of treatment.&#xD;
Number of items: 7 items; 1 week recall (for items on symptoms and rescue inhaler use)&#xD;
Number of domains &amp; categories: ACQ has a multidimensional construct assessing symptoms (5 items--self-administred) and rescue inbronchodilator use (1 item-self-administered), and FEV1% (1 item) completed by clinic staff&#xD;
Scaling of items: 7-point scale (0=no impairment, 6= maximum impairment for symptoms and rescue use; and 7 categories for FEV1%). Scores range between 0 (totally controlled) and 6 (severely uncontrolled).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">347</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Masitinib (titration to 6.0 mg/kg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive matched placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Masitinib</intervention_name>
    <arm_group_label>Masitinib (titration to 6.0 mg/kg/day)</arm_group_label>
    <other_name>AB1010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo Oral Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion criteria include:&#xD;
&#xD;
          -  Patients with a physician diagnosis of persistent asthma for at least 12 months based&#xD;
             on Global Initiative for Asthma (GINA) 2009 Guidelines whose asthma is partially&#xD;
             controlled or uncontrolled on inhaled corticosteroids (ICS) / long-acting&#xD;
             beta2-agonists (LABA) combination therapy.&#xD;
&#xD;
          -  Patient with elevated eosinophil level related to asthma at baseline: ≥0.15 K/uL or&#xD;
             patient with eosinophil level ≥0.15 K/uL related to asthma demonstrated in the year&#xD;
             prior to screening&#xD;
&#xD;
          -  Non-smoker patient for at least one year and with a prior tobacco consumption &lt;10&#xD;
             packs/year&#xD;
&#xD;
        Main exclusion criteria include:&#xD;
&#xD;
          -  Female patient who is pregnant or lactating&#xD;
&#xD;
          -  Asthmatic patient still exposed to allergens or to triggering factors influencing&#xD;
             asthma control&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease and/or other lung diseases impairing Pulmonary&#xD;
             Function Tests&#xD;
&#xD;
          -  Within 12 weeks prior to screening, patient who received oral corticosteroids for any&#xD;
             other reason than to treat severe asthma exacerbation (patients needing long term&#xD;
             corticosteroids intake to control basal asthma condition)&#xD;
&#xD;
          -  Patient with history of acute infectious sinusitis or respiratory tract infection&#xD;
             within 4 weeks prior to screening visit&#xD;
&#xD;
          -  Patient with active lung disease other than asthma (e.g. chronic bronchitis)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lavinia Davidescu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Medicine and Pharmacy Oradea, Oradea, Romania.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Respiratorio Quilmes</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarawak General Hospital</name>
      <address>
        <city>Kuching</city>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de los Andes</name>
      <address>
        <city>Miraflores</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Philippine Heart Center</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National institute of phthisiology and pulmonology named after F.G. Yanovsky NAMS of Ukraine</name>
      <address>
        <city>Kiev</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Malaysia</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Hungary</country>
  </removed_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 7, 2018</study_first_submitted>
  <study_first_submitted_qc>December 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2018</study_first_posted>
  <disposition_first_submitted>December 7, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>December 7, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 8, 2020</disposition_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe persistent asthma</keyword>
  <keyword>Eosinophil</keyword>
  <keyword>Tyrosine kinase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

